Madrigal Pharmaceuticals Q3 EPS $1.83 Beats $(0.94) Estimate, Sales $431.268M Beat $404.264M Estimate
Benzinga Newsdesk 4 days ago
NewsEarningsEarnings Beats
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over losses of $(5.08) per
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over losses of $(5.08) per share from the same period last year. The company reported quarterly sales of $431.268 million which beat the analyst consensus estimate of $404.264 million by 6.68 percent. This is a 50.13 percent increase over sales of $287.268 million the same period last year.